Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 9/20 | 0.64 |
| ▸ | CTSK | P43235 | 9/20 | 0.64 |
| ▸ | CTSB | P07858 | 3/20 | 0.64 |
| ▸ | CTSL | P07711 | 1/20 | 0.64 |
| ▸ | ACE | P12821 | 1/20 | 0.61 |
| ▸ | AKT1 | P31749 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 2/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5651916 | 1.00 | CTSS (0.64) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL7269746 | 0.92 | CTSS (0.70) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL20976440 | 0.88 | CTSS (0.65) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL6950132 | 0.86 | CTSS (0.64) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL7500508 | 0.86 | CTSS (0.64) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL6950136 | 0.86 | CTSS (0.64) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL67020 | 0.86 | ACE (0.79) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL21473784 | 0.86 | ACE (0.79) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL795685 | 0.86 | ACE (0.79) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL66220 | 0.86 | ACE (0.79) | CTSSCTSKCTSBCTSLACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307184-B2 | Processes for preparing oxazolidinone derivatives of β-hydroxyethlamine compounds and for preparing β-hydroxyethlamine compounds | KANEKA CORPORATION (JP) | 2007-12-11 | — | — | US | disclosed |
| US-20060135784-A1 | PROCESS FOR PRODUCING 3-AMINO-2-HYDROXYPROPIONIC ACID DERIVATIVES | KANEKA CORPORATION | 2006-06-22 | — | — | US | disclosed |
| US-7057066-B2 | Process for producing 3-amino-2-hydroxypropionic acid derivatives | KANEKA CORPORATION (JP) | 2006-06-06 | — | — | US | disclosed |
| US-20040181074-A1 | Process for producing oxazolidinone derivative of beta-hydroxyethylamine compound and for producing beta-hydroxyethlamine compound | KANEKA CORPORATION (JP) | 2004-09-16 | — | — | US | disclosed |
| EP-1403257-A1 | PROCESSES FOR PRODUCING OXAZOLIDINONE DERIVATIVE OF BETA-HYDROXYETHYLAMINE COMPOUND AND FOR PRODUCING BETA-HYDROXYETHYLAMINE COMPOUND | KANEKA CORPORATION (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20040049074-A1 | Process for producing 3-amino-2-hydroxypropionic acid derivatives | KANEKA CORPORATION (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1300391-A1 | PROCESS FOR PRODUCING 3-AMINO-2-HYDROXYPROPIONIC ACID DERIVATIVES | KANEKA CORPORATION (JP) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040049074-A1 | Process for producing 3-amino-2-hydroxypropionic acid derivatives | AASDHPPT, HPD, HAAO | CTSS 3991/4885CTSK 4195/4885CTSB 3958/4885 |
| US-20060135784-A1 | PROCESS FOR PRODUCING 3-AMINO-2-HYDROXYPROPIONIC ACID DERIVATIVES | AASDHPPT, HPD, HAAO | CTSS 3969/4885CTSK 4195/4885CTSB 3945/4885 |
| US-20040181074-A1 | Process for producing oxazolidinone derivative of beta-hydroxyethylamine compound and for producing beta-hydroxyethlamine compound | HNMT, PNMT, HRH4 | CTSS 4295/4885CTSK 2465/4885CTSB 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.